Category Archives: Agency Insight

Putting the M Back in M&A

By Jennifer Ringler | Published: December 13, 2011
Joe Panetta, president and CEO of BIOCOM, discusses an emerging model of M&As in which human and IP assets are valued and biotech brings expertise to Big Pharma as venture capitalist funding dwindles and patent cliffs loom large. Pharm Exec: Can you tell me about how small biotech and specialty companies have started switching from relying [...]
Also posted in Biotech, Deals, FDA | Tagged , , , | Leave a comment

The HCR Taxman Cometh

By Guest Blogger | Published: September 13, 2011
By Tom Norton As the country struggles with the current economic malaise, and the pharmaceutical industry enters into yet another difficult quarter of “trying to make the numbers,” one matter that I doubt many Rx execs are thinking about today is the HCR Taxman.  That’s too bad.  They probably should.  That’s because he’s coming for the [...]
Also posted in Advertising, Biotech, Corporate Responsibility, Strategy, compliance | Comments closed

Doing More With Less: A Leadership Perspective

By Jennifer Ringler | Published: July 19, 2011
Steven Blum, Director of Health Economics at Forest Laboratories and one of Pharm Exec’s 2011 Emerging Pharma leaders, recently spoke with Associate Editor Jennifer Ringler on building leadership and team rapport in today’s lean organization.
Also posted in Corporate Responsibility, leadership | Tagged , , , , , | 2 Comments

Mining Data to Gain a Competitive Edge

By William Looney | Published: June 7, 2011
When gauging influence in oncology prescribing, membership in the “club” still counts As the cancer therapeutics space grows more crowded, the task of identifying and building productive relationships with “key influencers” has become vital to a successful launch strategy.  Like everything else in oncology, performing that task is harder today. What was once an inbred club [...]
Also posted in Europe, Strategy | Tagged , | Leave a comment

Biosimilars Spend to Reach $2.5 Bln by 2015: IMS

By Ben Comer | Published: May 18, 2011
Global spending on biosimilars is expected to reach between $2 and $2.5 billion by 2015, up from $311 million in 2010, according to an IMS forecast. Total spend on biologics is expected to climb as high as $200 billion. On a call with reporters yesterday, Murray Aitken, executive director of the IMS Institute for Healthcare Informatics, [...]
Also posted in Biotech, Emerging Markets, Europe, Strategy | Tagged , , | 1 Comment